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Abstract 
Purpose: To improve the solubility of simvastatin (SV) by co-crystallization using nicotinamide (Nic) as 
co-crystal agent (co-former).  
Methods: In silico molecular modeling of Nic counter to SV were investigated using Auto Dock 4.2. Co-
crystal of Nic-SV was obtained by solvent evaporation (SE) using an equimolar ratio of Nic and SV. Co-
crystal of SV-Nic was evaluated by scanning electron microscopy (SEM), saturated solubility, intrinsic 
dissolution, x-ray powder diffraction (XRPD), differential scanning calorimetric (DSC), infrared 
spectrophotometry (FT-IR), binary phase diagram, and for stability at 40 oC and relative humidity (RH) 
75% in one month.  
Results: In silico results showed that the interaction of Nic with SV took place through hydrogen 
bonding as the synthon agent. The solubility and intrinsic dissolution properties of the co-crystal 
improved significantly compared to pure SV. Characterization of the co-crystal SV: Nic (1: 1) by SEM, 
XRPD, DSC, FT-IR, and binary phase diagram indicate the formation of a new solid phase that was 
different from either SV or Nic. Furthermore, the cocrystal of SV: Nic remained stable for one month. 
Conclusion: Co-crystallization using Nic has the potential to enhance drug solubility, intrinsic 
dissolution, and the stability of solution.  
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The effectiveness of drug delivery to a target 
organ or system in the body depends on the 
capability to produce suitable formulation of the 
drug. Deficiencies in the possessions of the solid 
pharmaceutical ingredient, such as solubility and 
bioavailability, have proved to be a major 
stumbling block in the successful manufacturing 
of medicines. The bioavailability of an oral 
preparation depends on its solubility which 
determines how quickly it is absorbed in the 
gastrointestinal tract and its permeability over cell 
membranes [1]. In pharmaceutical practice, 
many drugs show poor solubility in water, leading 
to problems with regard to dissolution and 
bioavailability [2]. Several drugs, including BCS 
class II and intravenous (IV) drugs like 
simvastatin (SV), have problems with solubility. 
 
SV is an inhibitor of A (HMG-CoA) reductase; it 
belongs to the class of statins. Statins are the 
drugs of choice for the management of 
hypercholesterolemia due to their recognized 
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efficacy and safety profile [3]. However, SV has a 
low solubility at about 30 µg/mL; moreover its 
bioavailability is only 5 % [4]. Several methods 
have been developed to improve the solubility of 
SV, such as solid dispersion [5], reduction of 
particle size micro emulsion [6], addition of a 
surfactant [7], but these methods have been 
somewhat insufficient. They have some 
shortcomings including, the high energy required 
of the process. Also, they involve the use of a 
number of matrices, and furthermore the 
upscaling process is complicated [4].  
 
Co-crystallization is an emerging crystal 
engineering techniques used for modulating 
solid-state properties of the API in order to 
enhance pharmaceutical performance. This is 
possible since co-crystallization develops new 
solid forms with structures that are different from 
the constituent molecules [8].  Co-crystallization 
is a relatively recent technology. It has been 
reported to increase the solubility and dissolution 
profile of a water insoluble drugs [9] and is 
consequently considered a potential method for 
enhancing the bioavailability of drugs with low 
solubility.  
 
Several techniques have been explored to 
formulate co-crystals, such as melting extrusion 
[10], supercritical fluids [11], forming a slurry with 
ultrasound [12], micronize particles [13], solid 
grinding [14], spray drying [15], and solvent 
evaporation (SE) [16]. The SE method is widely 
used in pharmaceutical manufacturing [17]. In 
the present work, we developed a simple 
technique of co-crystallization to improve the 





Simvastatin was obtained from Teva (Belgium) 
with purity > 99 %). Methanol pro analysis was 
obtained from Merck (Germany), and 
nicotinamide pro analysis was obtained from 
Sigma-Aldrich (Germany).  Furthermore, 
potassium dihydrogen phosphate pro analysis 
was sourced from Merck (Germany). 
 
In silico molecular docking simulation 
 
The 3D-structures of SV and Nic were built using 
LigandScout 4.1 and energy minimization by 
MM+. Moreover, the compound conformations 
were produced using the Discovery Studio 2.5 
with CATALYST finest conformation module. 
Chemistry at harvard macromoleculer mechanic 
(CHARMM forced field was applied for energy 
optimization. Molecular Docking simulations of 
the molecules were done as follow Ikram et al 
[18]. The AutoDockTools (ADT) script was 
directed to convert the ligand protein data bank 
(PDB) to the protein bank charge partial (PBQ) 
format. Also, Gasteiger charges were added and 
polar hydrogen was inspected. 
 
Co-crystal synthesis by solvent evaporation 
 
SV and Nic, accurately weighed in the molar ratio 
of 1:1 were mixed and diluted assisted by 
methanol, shaken for 10 min, and later stored in 
a water bath at 30 oC for 24 h for drying. The 
cocrystal thus obtained was stored in room 
temperature.  
 
Scanning electron microscopy (SEM) 
 
The external morphology of the samples (co-
crystals of SV-Nic) was examined using SEM 
(JSM6360A, JEOL, USA). Samples were placed 
on a double-handled sticky tape sputtered by 
platinum. Scanning photos were reserved at an 
accelerating step of 5 kV. 
 
Saturated solubility studies 
 
Dried co-crystal equivalently to SV 100 mg of 
reconstituted with 50 mL of distilled water in a 
vial. It was shaken for 24 h using an agitator 
shaker, the concentration of dissolved SV was 
determined using validated Uv-Vis 
spectrophotometry (Analytical Zena, Germany). 
The procedure was repeated for pure SV, and 
physical mixture of SV: Nic (1:1). 
 
Intrinsic dissolution studies 
 
The intrinsic release behaviors of the SV and its 
co-crystals were determined using a dissolution 
tester (USP type two: paddle apparatus). A co-
crystal equal to 250 mg SV in powders was 
compressed into pellet forms with hardness 30 
KgF, then put into a 900 mL simulated intestinal 
fluid (less enzyme) pH 4.5 stirred at 100 rpm. 
Sampling (5 mL) was done at 10 min interval up 
to 60 min a fresh 5 mL SIF solution was added 
into the system to replenish withdrawn samples 
after each sampling. Each sample withdrawn 
was filtered through a syringe filter of 0.45 μm 
pore size, and its UV absorbance was measured 
at 240 nm (spectrophotometer, Analytical Zena, 
Germany). SV concentration was calculated 
using a validated pre-constructed calibration 
curve. The same procedure was repeated for 
pure SV dissolution procedure. 
 
Fourier transforms infra-red (FT-IR) 
spectrophotometry studies 
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Powdered samples were mixed with potassium 
bromide crystal at the molar ratio (1: 10), and 
then compressed at a pressure of 20 psi. The 
spectra were analyzed over a range of 
wavenumbers 4000-400 cm–1, using FT-IR 
(Specord 200, Germany). 
 
X-ray powder diffraction(XPD) analysis  
 
The x-ray powder diffractometer (X Philips 
Analytical PW1710, Germany) arrays were 
collected using Cu Ka radiation (l = 1.54 Å), a 
duct stage of 40 kV and a duct current of 40 mA. 
Records were collected from 2Ɵ angle 5o - 48o at 
a constant image rate of 4 o/min. 
 
Thermal analysis  
 
Thermal analysis of the samples was carried out 
on a DSC/TGA apparatus (Linseis PTA ST 1600, 
Germany) which was adjusted for heat and cell 
constants using indium. Samples (2 – 3 mg) 
crumpled in the aluminium pan were examined 
from 50-300 oC at a heating rate of 10 oC/min. 
Samples were constantly purged with nitrogen at 
50 ml/min. 
 
Preparation of binary phase diagram 
 
The binary phase diagram is made by making 
the mixture with SV: Nic with mole fraction 
comparison among SV-Nic (0:10) until (10:0), 
then each mixture was measured at its melting 
point, afterward, it was plotted in the charts form. 
 
Stability studies  
 
Profile of co-crystal stability SV: Nic (1:1) was 
examined thru observing a melting point of the 
co-crystal that were kept in a storage condition 




In silico studies (Figure 1) revealed that the 
lowest Gibbs-free energy of molecule 
conformation was -2.5 kcal/ mole and distance of 
the bonding was 2.168 Å. 
 
Figure 1: In silico molecular interaction model of SV 
and Nic 
 
SEM of co-crystal of SV-Nic (1:1) 
 
SEM (Figure 2) show particle size and surface 
morphology of pure SV and co-crystal. Co-crystal 
of SV: Nic (1:1) presented a more compact 
structure with a higher density. 
 
Saturation solubility  
 
Result of the saturated solubility of co-crystal 
show a threefold increase compared to SV and 
the PM. Cocrystal SV-Nic 1:1 reached 30 µg/mL 
and SV was 9 µg/mL. 
 
Intrinsic dissolution  
 
The dissolution value of the co-crystal SV-Nic 
(1:1) shows an increase by approximately four 
times (400 %) compared to the value of pure SV 




The spectrum overlay of pure SV, Nic and co-
crystal SV-Nic (1:1) show the widening of the co-







Figure 2: SEM of Nic (a), SV (b), Co-crystal SV-Nic (c) 
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Figure 3: Intrinsic dissolution profile of co-crystal SV-Nic 1:1 (a) and pure SV (b) (n= 6) 
 
 
    Figure 4: Spectrum of Nic (a), Co-crystal SV-Nic (b) and SV (c) 
 
 




The thermogram (Figure 5) reveal that the 
melting point (endotherm phase) of co-crystal 
SV-Nic (105.7 °C) < pure SV (135.8 °C). The 
enthalpy of SV (-74.4 Joule/g) > co-crystal SV-
Nic 1:1 (-80.68 Joule/g). 
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        Figure 6: Diffractogram of SV (a), co-crystal SV: Nic 1:1 (b), and PM of SV: Nic (c) 
 
 




The XRPD verify the formation of co-crystal of 
SV: Nic (1:1) as compared to SV and its PM. The 
diffractogram show distinct peaks and intensity at 
17 - 20°, and 20 - 30°. (Figure 6). 
 
Binary phase diagram 
 
The binary phase diagram (Figure 7) showed 
distinct eutectics points at the mole fractions of 
(4:6), (5:5) and (6:4). At (5:5) point, the melting 




The thermograms (Figure 8) showed no change 
in melting point at 105.5 oC Co-crystal for 1 





Figure 8: Thermogram overlay of co-crystal SV:Nic 
(1:1) for 10 day (a), 20 day (b), and 30 day (c) 
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In silico studies by molecular modeling have 
been performed as a simple tool to study the 
hydrogen bonding of the SV and Nic [19]. The 
negative value of Gibbs-free energy obtained 
through in silico simulation modeling indicates 
that the interaction of SV and Nic occurred 
spontaneously. The interaction of SV and Nic 
takes place through hydrogen bonds that have 
been categorized as the hetero-synthon for this 
co-crystal. SV and Nic shows very close bonding 
and also allows the existence of the hydrogen 
bonds.   SE method was used because it yielded 
co-crystals of a high degree of purity using co-
crystal constituents in an equimolar ratio, and the 
solvent also served as the catalyst [1]. 
 
SEM showed that the co-crystals had a more 
compact structure with higher density. This was 
due to the hydrogen bonding interaction of the 
SV and Nic in co-crystal form. Previous studies 
have also indicated that a hydrogen bonding has 
an important part in the molecular interaction of 
co-crystallization [20]. Nic was chosen as the co-
former for considerations such as polarity, 
availability of synthon and stability. The increase 
in the solubility and dissolution rate was caused 
by the intensified affinity of the solvent to SV. It 
was initiated by the existence of the co-former, 
apart from the decrease in the energy of the 
crystal lattice via co-crystal formation [12].  
 
FT-IR is a general spectroscopic approach that is 
very effective to determine co-crystal, since the 
formation of a co-crystal involves hydrogen 
bonds [21]. The spectrum has shown a 
broadening peak as a result of the intermolecular 
hydrogen bonding, and this is especially 
applicable to the peak at 3.545 cm
−1
. It is 
specifically related to intermolecular hydrogen 
bonding formation.  
A decrease in the melting point and heat content 
of the co-crystal will directly correlate to 
increased solubility of the API in the co-crystal. 
The melting point of the co-crystal would fall 
between the melting points of the API and its co-
former [22]. 
 
X-ray powder diffraction is a specific technique to 
confirm whether the new solid state and the 
pharmaceutical co-crystal are prone to forming 
isostructural phases [23]. The intensity of the 
emissions from the co-crystal showed a 
decreasing tendency in intensity due to changes 
in crystal habits [24]. Consequently, a number of 
distinct co-crystal peaks were obtained as 
compared to the PM, thus indicating a different 
structure.  
 
The binary phase diagram exhibited three lowest 
points forming a W pattern. This may be 
interpreted as the pattern of co-crystal habits 
[25]. DSC was used to observe the stability of the 
co-crystal, as studying the temperature and 
relative humidity is the most established method 
to assess stability in solid state [26]. The melting 
point and XRPD pattern on days 10, 20 and 30 
respectively showed constant values. It was 
confirmed that the co-crystal remained stable for 
a term of one month under storage conditions of 




Preparation of the co-crystal of SV with co-former 
Nic (1:1) has been successfully carried out using 
solvent evaporation method. Evaluation of the 
saturated solubility and intrinsic dissolution of 
SV: Nic (1:1) co-crystal indicate that the solubility 
rate and release behaviour of SV-Nic co-crystal 
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